Search Results 191-200 of 17312 for Teratogenic

  1. Low-Dose Selinexor and Choline Salicylate for the Treatment of Patients With Non-Hodgkin Lymphoma or Histiocytic/Dendritic Cell Neoplasms - Mayo Clinic

    genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown: - Pregnant women - Nursing women - Co-morbid systemic ...

  2. A Study to Evaluate the Safety, Tolerability, and Determine the Optimal Dose for the Expansion Cohorts of VSV-IFNβ-NIS in Combination with Pembrolizumab in Patients with Refractory Solid Tumors - Mayo Clinic

    Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn ...

  3. A Study to Evaluate Docetaxel With or Without Bintrafusp Alfa to Treat Patients with Advanced Non-small Cell Lung Cancer - Mayo Clinic

    Participation eligibility · Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the ...

  4. Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery - Mayo Clinic

    Any of the following because this study involves an agent where the genotoxic, mutagenic and teratogenic effects are unknown: Pregnant or breastfeeding ...

  5. Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery - Mayo Clinic

    Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn ...

  6. Synergy with Grid Therapy and Immune Checkpoint Inhibitors in Stage IV Non-Small Cell Lung Cancer - Mayo Clinic

    Any of the following because this study involves an investigational agent whose genotoxic, mutagenic, and teratogenic effects on the developing fetus and ...

  7. Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer - Mayo Clinic

    Pregnant women are excluded from this study because paclitaxel, doxorubicin, and cyclophosphamide have the potential for teratogenic or abortifacient effects.

  8. A Study to Evaluate Durvalumab plus Topotecan or Lurbinectedin in Patients with Small Cell Lung Cancer - Mayo Clinic

    Participation eligibility · Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the ...

  9. A Study to Evaluate Abemaciclib for Surgically Resectable, Chemotherapy-Resistant, Triple Negative Breast Cancer - Mayo Clinic

    Participation eligibility · Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the ...

  10. Non Clinical Trials - Mayo Clinic Research

    Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as CC-486, cyclophosphamide, ...